Consequently, YH1 potentially inhibited the activity of intestinal FXR, thereby decreasing hyperlipidemia by reducing negative feedback regulation and promoting the conversion of hepatic cholesterol to BAs. This evidence concerns the gene NR1H4 and hyperlipidemia.